ArticleFrontiers in microbiology2017
A Novel IncA/C1 Group Conjugative Plasmid, Encoding VIM-1 Metallo-Beta-Lactamase, Mediates the Acquisition of Carbapenem Resistance in ST104
Article in Frontiers in microbiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Prevalence and clonal diversity of carbapenem-resistant Klebsiella pneumoniae causing neonatal infections: A systematic review of 128 articles across 30 countries.PLoS medicine · 2023Pooled it
- Mobile genetic elements encoding antibiotic resistance genes and virulence genes inFrontiers in microbiology · 2025Review
- The biogenesis of β-lactamase enzymes.Microbiology (Reading, England) · 2022Review
- Metallo-β-lactamases in the Age of Multidrug Resistance: From Structure and Mechanism to Evolution, Dissemination, and Inhibitor Design.Chemical reviews · 2021Review
- Undetectable Production of the VIM-1 Carbapenemase in anFrontiers in microbiology · 2021Article
- Neonatal Sepsis: The Impact of Carbapenem-Resistant and HypervirulentFrontiers in medicine · 2021Review
- Emerging Transcriptional and Genomic Mechanisms Mediating Carbapenem and Polymyxin Resistance inmSystems · 2020Review
- A Multispecies Cluster of VIM-1 Carbapenemase-ProducingAntimicrobial agents and chemotherapy · 2020Article
- Epidemic Characteristics of Carbapenem-ResistantInfection and drug resistance · 2020Article
- Clinical and Molecular Epidemiologic Characteristics of Ceftazidime/Avibactam-Resistant Carbapenem-ResistantInfection and drug resistance · 2020Article
- Evolution of Carbapenem-Resistant Serotype K1 Hypervirulent Klebsiella pneumoniae by Acquisition ofAntimicrobial agents and chemotherapy · 2019Article
- Protein determinants of dissemination and host specificity of metallo-β-lactamases.Nature communications · 2019Article
- Interplay among IncA andAntimicrobial agents and chemotherapy · 2019Article
- Marine biofilms constitute a bank of hidden microbial diversity and functional potential.Nature communications · 2019Article
- Extended-spectrum β-lactamase-producing and carbapenemase-producing Enterobacteriaceae.Microbial genomics · 2018Review
- Spread of Clonally Related Escherichia coli Strains Harboring an IncA/CAntimicrobial agents and chemotherapy · 2018Article
- Complete Sequence of the IncA/CAntimicrobial agents and chemotherapy · 2018Article
- Molecular Epidemiology and Virulence Profiles of Colistin-ResistantFrontiers in microbiology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emergence of carbapenemase producing Enterobacteriaceae has raised major public health concern. The aim of this study was to investigate the molecular epidemiology and the mechanism of carbapenem resistance acquisition of multidrug-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.